Jo Uk-je, CEO of Yuhan Corporation, "Focused on Exceeding Targets and Enhancing Shareholder Value"

Jo Wook-je, CEO of Yuhan Corporation, is speaking at the 102nd Annual General Meeting of Shareholders held on the 20th in the training room of the headquarters in Daebang-dong, Dongjak-gu, Seoul. Photo by Yuhan Corporation

On the 20th, Jo Wook-je, CEO of Yuhan Corporation, stated at the regular shareholders' meeting, "We will make every effort to exceed the established goals and enhance shareholder value."

In his greeting at the 102nd regular shareholders' meeting held at the training room of the headquarters in Daebang-dong, Dongjak-gu, Seoul, CEO Jo said, "Thanks to the passionate support of our shareholders and the dedicated efforts of all employees, the non-small cell lung cancer treatment 'Reclaza' received FDA approval in the United States last August as the first domestically produced anticancer drug and as a first-line therapy in combination treatment." He added, "We were able to achieve the milestone of surpassing 2 trillion KRW in net sales, a first in the domestic pharmaceutical industry."

Yuhan Corporation's non-small cell lung cancer treatment Reclaza was approved by the FDA as a combination therapy with the anticancer drug 'Rybrevant' from the global pharmaceutical company Johnson & Johnson (J&J). At the shareholders' meeting, Yuhan Corporation decided to pay a cash dividend of 500 KRW per common share and 510 KRW per preferred share (totaling 37.5 billion KRW). The articles of incorporation related to the dividend record date were also partially amended.

This content was produced with the assistance of AI translation services.